These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 9298430)

  • 1. Response to treatment in minor and major depression: results of a double-blind comparative study with paroxetine and maprotiline.
    Szegedi A; Wetzel H; Angersbach D; Philipp M; Benkert O
    J Affect Disord; 1997 Sep; 45(3):167-78. PubMed ID: 9298430
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A double-blind study comparing paroxetine and maprotiline in depressed outpatients.
    Szegedi A; Wetzel H; Angersbach D; Dunbar GC; Schwarze H; Philipp M; Benkert O
    Pharmacopsychiatry; 1997 May; 30(3):97-105. PubMed ID: 9211571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose escalation vs. continued doses of paroxetine and maprotiline: a prospective study in depressed out-patients with inadequate treatment response.
    Benkert O; Szegedi A; Wetzel H; Staab HJ; Meister W; Philipp M
    Acta Psychiatr Scand; 1997 Apr; 95(4):288-96. PubMed ID: 9150822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A double-blind, multicentre study of paroxetine and maprotiline in major depression.
    Schnyder U; Koller-Leiser A
    Can J Psychiatry; 1996 May; 41(4):239-44. PubMed ID: 8726790
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A double-blind study of paroxetine, fluoxetine, and placebo in outpatients with major depression.
    Fava M; Amsterdam JD; Deltito JA; Salzman C; Schwaller M; Dunner DL
    Ann Clin Psychiatry; 1998 Dec; 10(4):145-50. PubMed ID: 9988054
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic superiority of maprotiline versus doxepin in geriatric depression.
    Gwirtsman HE; Ahles S; Halaris A; DeMet E; Hill MA
    J Clin Psychiatry; 1983 Dec; 44(12):449-53. PubMed ID: 6361005
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A double-blind, multicenter study in primary care comparing paroxetine and clomipramine in patients with depression and associated anxiety. Paroxetine Study Group.
    Ravindran AV; Judge R; Hunter BN; Bray J; Morton NH
    J Clin Psychiatry; 1997 Mar; 58(3):112-8. PubMed ID: 9108813
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paroxetine versus placebo: a double-blind comparison in depressed patients.
    Claghorn JL; Kiev A; Rickels K; Smith WT; Dunbar GC
    J Clin Psychiatry; 1992 Dec; 53(12):434-8. PubMed ID: 1487471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The serotonin reuptake inhibitor paroxetin is superior to the noradrenaline reuptake inhibitor maprotiline in the treatment of premenstrual syndrome.
    Eriksson E; Hedberg MA; Andersch B; Sundblad C
    Neuropsychopharmacology; 1995 Apr; 12(2):167-76. PubMed ID: 7779245
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Placebo-controlled trial of mianserin and maprotiline in primary depressive illness: a preliminary report.
    Edwards JG; Goldie A
    Br J Clin Pharmacol; 1983; 15 Suppl 2(Suppl 2):239S-248S. PubMed ID: 6337611
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A double-blind comparison of fluvoxamine and paroxetine in the treatment of depressed outpatients.
    Kiev A; Feiger A
    J Clin Psychiatry; 1997 Apr; 58(4):146-52. PubMed ID: 9164424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of paroxetine and placebo in depressed outpatients.
    Dunbar GC; Claghorn JL; Kiev A; Rickels K; Smith WT
    Acta Psychiatr Scand; 1993 May; 87(5):302-5. PubMed ID: 8517168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
    Detke MJ; Wiltse CG; Mallinckrodt CH; McNamara RK; Demitrack MA; Bitter I
    Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of moclobemide compared with maprotiline in treatment of major depressive disorder. A double-blind multicenter study with parallel groups.
    Steinmeyer EM; Vorbach EU; Arnoldt KH
    Pharmacopsychiatry; 1993 Nov; 26(6):246-53. PubMed ID: 8127929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of amisulpride 50 mg versus paroxetine 20 mg in major depression: a randomized, double-blind, parallel group study.
    Cassano GB; Jori MC;
    Int Clin Psychopharmacol; 2002 Jan; 17(1):27-32. PubMed ID: 11800503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of tianeptine in major depression: evidence from a 3-month controlled clinical trial versus paroxetine.
    Waintraub L; Septien L; Azoulay P
    CNS Drugs; 2002; 16(1):65-75. PubMed ID: 11772119
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A double-blind comparison of paroxetine and placebo in the treatment of depressed outpatients.
    Claghorn J
    Int Clin Psychopharmacol; 1992 Jun; 6 Suppl 4():25-30. PubMed ID: 1431007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized, double-blind study of fluoxetine and maprotiline in the treatment of major depression.
    de Jonghe F; Ravelli DP; Tuynman-Qua H
    Pharmacopsychiatry; 1991 Mar; 24(2):62-7. PubMed ID: 1852793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Double-blind multicenter study of paroxetine and amitriptyline in depressed inpatients.
    Möller HJ; Berzewski H; Eckmann F; Gonzalves N; Kissling W; Knorr W; Ressler P; Rudolf GA; Steinmeyer EM; Magyar I
    Pharmacopsychiatry; 1993 May; 26(3):75-8. PubMed ID: 8415897
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A double-blind comparison of paroxetine, imipramine and placebo in depressed outpatients.
    Feighner JP
    Int Clin Psychopharmacol; 1992 Jun; 6 Suppl 4():31-5. PubMed ID: 1431008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.